Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Feb 22 04:00PM ET
8.30
Dollar change
+0.09
Percentage change
1.10
%
Index- P/E- EPS (ttm)- Insider Own57.15% Shs Outstand47.61M Perf Week12.01%
Market Cap395.16M Forward P/E- EPS next Y- Insider Trans5.70% Shs Float20.40M Perf Month-
Income- PEG- EPS next Q- Inst Own- Short Float- Perf Quarter-
Sales- P/S- EPS this Y- Inst Trans- Short Ratio- Perf Half Y-
Book/sh-6.45 P/B- EPS next Y- ROA- Short Interest- Perf Year-
Cash/sh0.94 P/C8.82 EPS next 5Y- ROE- 52W Range6.91 - 14.50 Perf YTD-35.41%
Dividend Est.- P/FCF- EPS past 5Y- ROI- 52W High-42.76% Beta-
Dividend TTM- Quick Ratio5.57 Sales past 5Y0.00% Gross Margin- 52W Low20.03% ATR (14)1.31
Dividend Ex-Date- Current Ratio5.57 EPS Y/Y TTM- Oper. Margin- RSI (14)- Volatility13.82% -
Employees- Debt/Eq- Sales Y/Y TTM- Profit Margin- Recom- Target Price-
Option/ShortNo / Yes LT Debt/Eq- EPS Q/Q-49.49% Payout- Rel Volume0.27 Prev Close8.21
Sales Surprise- EPS Surprise- Sales Q/Q- Earnings- Avg Volume538.33K Price8.30
SMA20-10.99% SMA50-10.99% SMA200-10.99% Trades Volume153,002 Change1.10%
Fractyl Health develops innovative medical device solutions for the treatment of chronic diseases. The growing product pipeline leverages our minimally invasive procedural therapy, Revita DMR (duodenal mucosal resurfacing), which is designed to rejuvenate the lining of the duodenum and improve patient health. They envision a world with better solutions to chronic diseases through the use of less invasive, device-based therapies that will lessen the burden on patients, physicians, and payers. Fractyl Health aims to bring curative therapies to the large populations of patients with metabolic disease.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Elia MarcDirectorFeb 06Buy15.00466,6666,999,9901,856,117Feb 08 04:32 PM
CVF, LLC10% OwnerFeb 06Buy15.00333,3334,999,9954,673,870Feb 06 08:39 PM
Royan AjayDirectorFeb 06Buy15.00333,3334,999,9951,251,900Feb 08 04:37 PM
Mithril LP10% OwnerFeb 06Buy15.00333,3334,999,9951,251,900Feb 08 04:35 PM